The results are now in from our 2021 Priorities Survey. With your help, we have understood which of the many different areas of MS research and advocacy are considered the most important by people directly and indirectly affected by MS.
MS Australia President Associate Professor Des Graham presents ‘A world without MS: Strategic Plan 2022-2026’.
CEO Rohan Greenland gives an update on the MS Australia activities for the year ahead, focusing on the newly launched five-year strategic plan.
How your support is helping solve the biggest challenges of MS – and giving people like Amy their life back.
The COVID-19 pandemic is ever-evolving; however, we are constantly monitoring developments and providing the latest information on our website. Here we unpack the difference between a primary course of vaccination and boosters.
Researchers have explored the contributions of sun exposure and ultraviolet radiation (UVR) to the risk of children developing MS.
Soliris® (eculizumab), the first TGA-approved medication for NMOSD, has not been recommended for listing on the PBS.
New imaging data shows sustained improvement in disability and increases in myelin density in the brain following an experimental treatment for progressive MS.
CEO Rohan Greenland gives an update on the MS Australia activities for December, focusing on the year ahead for MS Australia.
